PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP 599 Lexington Avenue, 38th Floor New York, NY 10022
MEMORANDUM
I. Executive Summary
The purpose of this memorandum is to summarize the preliminary legal due diligence findings of Calderwood & Harkness LLP ("C&H") with respect to Vectris Photonics, Inc. ("Vectris" or the "Company") in connection with the proposed acquisition of Vectris by Halcyon Semiconductor Aktiengesellschaft ("Halcyon" or "HSAG") for an aggregate equity consideration of Eight Hundred Million Dollars ($800,000,000) in an all-cash reverse triangular merger (the "Transaction" or the "Merger"). This memorandum is being provided to the addressees in their respective capacities and is intended to assist the deal team in identifying key legal risks, informing the negotiation of the definitive Agreement and Plan of Merger (the "Merger Agreement"), and prioritizing areas requiring further investigation.
The virtual data room maintained by Vectris and its counsel, Whitfield, Prager & Loomis LLP ("WPL"), was opened on June 26, 2023. This memorandum covers our review of materials made available in the data room through approximately July 12, 2023. As described in Section II below, the data room continues to be populated and our review is ongoing.
Overall Assessment. Based on our preliminary review, Vectris is a well-organized Delaware C-corporation (Delaware Secretary of State File No. 5918437), headquartered at 4750 Ridgepoint Drive, Suite 300, San Jose, California 95134. The Company currently employs approximately 1,450 individuals and reported revenues of approximately $312 million and EBITDA of approximately $74 million for its fiscal year ended December 31, 2022 ("FY2022"). Vectris operates as a fabless designer of silicon photonics transceivers and co-packaged optics chiplets for hyperscale data center interconnects. The Company maintains important commercial relationships with three of the top five U.S. hyperscale cloud operators, which collectively represent its most significant sources of revenue.
Key Risk Areas. Our preliminary review has identified the following principal risk areas, each of which is discussed in detail in the body of this memorandum:
(a) Antitrust/Regulatory Approval Risk. There is significant competitive overlap between Halcyon and Vectris in the silicon photonics transceiver market, resulting in a combined U.S. market share of approximately 47%. This overlap presents a material risk of enhanced regulatory scrutiny, including the possibility of a Second Request from the U.S. Department of Justice and a Phase II investigation by the European Commission.
(b) IP Assignment Chain Issues. Preliminary review of the patent portfolio has identified approximately five to seven patents for which assignment documentation from early-stage employees may be incomplete. These chain-of-title issues require further investigation and potentially corrective action prior to or at closing.
(c) Customer Concentration. The Company's top three customers accounted for approximately 68% of FY2022 revenue. The loss of any single top-three customer could have a material adverse effect on Vectris's business, financial condition, and results of operations.
(d) Pending Employment-Related Litigation. A former senior engineer has filed a wrongful termination claim in Santa Clara County Superior Court alleging retaliation. While Vectris's outside employment counsel assesses the risk as low, the matter is in early discovery and warrants monitoring.
(e) Change-of-Control Provisions in Material Contracts. Two of three key customer agreements and the Company's revolving credit facility contain change-of-control provisions that will be triggered by the Merger. One customer agreement includes a right to terminate if the acquirer is deemed a "competitor" under the contract.
No issues have been identified to date that, individually or in the aggregate, would be expected to constitute a "Material Adverse Effect" on Vectris (as that term is expected to be defined in the Merger Agreement). However, several items warrant further investigation and should be addressed through carefully tailored representations, warranties, covenants, conditions, and disclosure schedules in the definitive Merger Agreement.
This memorandum should be read in conjunction with the following companion work product, which is being prepared in parallel:
• intellectual Property Due Diligence Memorandum, to be prepared by Tiffany Rosenthal and dated July 21, 2023, covering the patent portfolio (187 issued U.S. patents and 43 pending applications) and license agreements in greater depth.
• Antitrust Risk Assessment Memorandum, prepared by Howard Bellamy and dated July 10, 2023, covering HSR Act and EUMR filing obligations, competitive overlap analysis, and recommended regulatory strategy.
II. Scope and Methodology
Scope of Review. Our legal due diligence review has encompassed materials provided by Vectris and its counsel, WPL, through the Thackeray Solutions virtual data room (the "Data Room") established for purposes of the Transaction. The lead partner at WPL overseeing Vectris's sell-side process is Catherine Whitfield. We have also reviewed publicly available materials, including SEC filings, UCC filings, and court records, as appropriate.
The categories of materials reviewed to date include the following:
• Organizational and corporate governance documents, including the Restated Certificate of Incorporation, Amended and Restated Bylaws, and certificates of good standing;
• Capitalization records, including stock ledgers, option grant records, and equity incentive plan documentation;
• Board of Directors and stockholder minutes and written consents from January 2021 through June 2023;
• Material commercial contracts, including customer supply agreements, supplier and foundry agreements, and joint development agreements;
• Real property lease agreements for the Company's three principal office locations;
• Employment agreements for named executive officers and key personnel, employee benefit plan documents, and related compliance materials;
• Pending and threatened litigation files, including pleadings, correspondence, and outside counsel assessments;
• Environmental compliance records and assessments;
• Insurance policies and claims history;
• Regulatory filings and compliance program documentation, including export control compliance materials;
• intellectual property documents, including patent schedules, assignment records, and license agreements (preliminary review only, to be supplemented in the forthcoming IP Due Diligence Memorandum); and
• Tax materials, reviewed at a high level only.
Financial Statements. Vectris's audited financial statements for FY2020, FY2021, and FY2022 have been audited by Linden Ross & Co., LLP (engagement partner Christine Park). We have reviewed the audit opinions for each of these fiscal years, and each contains a clean, unqualified opinion with no emphasis of matter paragraphs or qualifications. While a detailed analysis of the financial statements is outside the scope of this legal memorandum, we have reviewed the financial data as context for assessing the Company's contractual obligations, litigation exposure, and overall financial condition.
Tax Due Diligence. Detailed tax due diligence is being conducted by Thornbury Wight LLP under the direction of engagement partner Gavin Ashmore. This memorandum addresses tax matters only at a preliminary and high level, and the findings set forth in Section IX below are subject to the more comprehensive analysis to be provided by Thornbury Wight.
Financial Advisors. We note that Clearwater Zanthor & Co., LLC (led by Diane Okoro) is serving as financial advisor to Vectris, and Ridgeline Partners LLC (led by Nathaniel Cross) is serving as financial advisor to Halcyon in connection with the Transaction. Financial analyses, valuation assessments, and fairness opinion matters are outside the scope of this legal memorandum and are not addressed herein.
Limitations. The Data Room continues to be populated, and Vectris has indicated through WPL that certain supplemental materials, including additional IP documentation, employment records for non-executive personnel, and certain historical regulatory filings, will be uploaded in the coming days. Accordingly, this memorandum reflects findings as of the review date of approximately July 12, 2023 and is necessarily preliminary. We reserve the right to update, supplement, or modify our findings and recommendations as additional materials become available and as our review progresses. Nothing in this memorandum should be construed as a comprehensive or final assessment of all legal risks associated with the Transaction.
III. Corporate Organization and Good Standing
A. Organizational Structure
Vectris Photonics, Inc. is a Delaware C-corporation, incorporated under the Delaware General Corporation Law (the "DGCL"), and registered with the Delaware Secretary of State under File No. 5918437. The Company's registered agent in Delaware is Capitol Corporate Services, LLC, located at 800 N. King Street, Suite 400, Wilmington, Delaware 19801.
Based on our review of the Data Room materials and publicly available information, Vectris does not have any subsidiaries, whether domestic or foreign. The Company operates entirely as a single legal entity. This relatively simple organizational structure simplifies the due diligence process and reduces the risk of undisclosed liabilities arising from subsidiary operations.
Vectris is qualified to do business as a foreign corporation in the following jurisdictions: California (the state in which its headquarters is located), Texas, Oregon, and New York. We have requested certificates of good standing from the Delaware Secretary of State and from the Secretary of State (or equivalent authority) in each qualification jurisdiction. The Delaware certificate of good standing has been received and confirms that Vectris is currently in good standing in its state of incorporation. Certificates from the remaining qualification jurisdictions are expected to be received within the next five to seven business days and will be reviewed upon receipt.
We have not identified any jurisdictions in which Vectris is conducting business but is not properly qualified to do so. However, we note that if Vectris has employees, offices, or significant business activities in jurisdictions beyond those identified above, additional qualifications may be required, and failure to qualify could result in penalties or the inability to maintain or defend legal proceedings in such jurisdictions. We recommend confirming with management that the Company's current state qualifications reflect all jurisdictions in which it has a meaningful business presence.
B. Charter Documents
We have reviewed the Company's Restated Certificate of Incorporation (the "Certificate") and Amended and Restated Bylaws (the "Bylaws"), each as currently in effect.
Restated Certificate of Incorporation. The Certificate contains standard provisions for a publicly traded Delaware corporation. The authorized capital stock consists of shares of common stock and shares of preferred stock. All previously outstanding shares of preferred stock were converted into shares of common stock at the time of Vectris's initial public offering in 2019, and no shares of preferred stock are currently outstanding. The Certificate does not contain any unusual restrictions on the transfer of shares, supermajority voting requirements beyond those imposed by the DGCL, or other non-standard provisions that would be expected to impede the Transaction.
Amended and Restated Bylaws. The Bylaws are consistent with standard Delaware corporation practice and provide for a board of directors composed of seven (7) members. The Bylaws set forth customary provisions regarding meetings of stockholders, meetings of the board of directors, committees of the board, officers, indemnification and advancement of expenses, and amendment procedures.
Anti-Takeover Provisions. We note that there is no stockholder rights plan (commonly referred to as a "poison pill") currently in effect. However, the Certificate provides for a classified board structure, with the seven directors divided into three classes serving staggered three-year terms. While a classified board is not uncommon among publicly traded companies, it is a structural anti-takeover device that, in the context of a friendly acquisition such as the Transaction, will require appropriate treatment. Specifically, the Merger Agreement should address the composition and classification of the surviving entity's board of directors following the effective time of the Merger.
C. Board and Governance
Board of Directors. The current board of directors of Vectris consists of the following seven individuals:
We have reviewed the minutes of meetings of the board of directors and its committees from January 2021 through June 2023. No irregular actions, unauthorized transactions, or governance irregularities have been noted based on our review. The minutes reflect orderly corporate governance practices, including regular quarterly board meetings, proper notice procedures, and achievement of quorum at all meetings.
Of particular relevance to the Transaction, the April 2023 board minutes evidence the board's formal approval of the engagement of Clearwater Zanthor & Co., LLC as financial advisor and Whitfield, Prager & Loomis LLP as legal counsel in connection with the exploration and evaluation of potential strategic transactions, including a possible sale of the Company. This approval was obtained upon the recommendation of the board's strategic review committee, which was formed in March 2023.
Officers. The current principal officers of Vectris are as follows:
• Dr. Anand Raghavan — Chief Executive Officer
• Margaret Sørensen — President and Chief Operating Officer
• Julian Tate — Chief Financial Officer
• Rebecca Lau — General Counsel and Corporate Secretary
D. Capitalization
Based on our review of the Company's capitalization records, public filings, and equity incentive plan documentation, the capitalization of Vectris is as follows:
At an aggregate equity consideration of $800,000,000, the implied per-share merger consideration is approximately $13.70 per share ($800,000,000 ÷ 58,394,160 fully diluted shares). For reference, the unaffected closing share price of Vectris common stock on May 19, 2023 (the last trading day prior to the date on which market rumors regarding the Transaction first appeared) was $9.82, implying a premium of approximately 39.5% to the unaffected share price. The Company's common stock trades on the Nasdaq Global Select Market under the ticker symbol "VTRS" and bears CUSIP number 92553P108.
Significant Stockholders. Based on the most recent proxy statement and Schedule 13D/13G filings available, the significant stockholders of Vectris are as follows:
Granite Peak Ventures Fund IV, L.P. and Nordhaven Capital Partners III, L.P. together hold approximately 37.2% of the outstanding shares and each have a designee on the board of directors. Their support (or opposition) to the Transaction will be an important factor in the stockholder approval process. We recommend that Halcyon and its advisors assess whether voting agreements or letters of support should be obtained from these significant stockholders in connection with the signing of the Merger Agreement.
Equity Incentive Plan. The Company maintains the Vectris Photonics, Inc. 2019 Equity Incentive Plan (the "Plan"), under which all outstanding stock options and RSUs have been granted. Exercise prices for outstanding options range from $3.50 to $9.15 per share, meaning that all outstanding options are in the money at the proposed per-share merger consideration of $13.70.
We have not identified any outstanding warrants, convertible notes, convertible debt instruments, or other potentially dilutive securities beyond the options and RSUs described above. We have also not identified any preemptive rights, rights of first refusal, or similar rights that would be triggered by the issuance or transfer of shares in connection with the Merger.
Open Item. We have requested that Rebecca Lau, Vectris's General Counsel and Corporate Secretary, provide a complete capitalization table as of a recent date, certified by Ms. Lau, for inclusion as part of Disclosure Schedule 3.4 (Capitalization) to the Merger Agreement. The certified capitalization table should reflect all outstanding shares, options, RSUs, and any other equity-linked instruments, together with vesting schedules, exercise prices, and grant dates. We anticipate receiving this certified table no later than July 18, 2023.
IV. Material Contracts
We have conducted a review of the material commercial contracts made available in the Data Room. Our findings are summarized below by contract category.
A. Customer Agreements
Revenue Concentration. Vectris derives a significant majority of its revenue from three of the top five U.S. hyperscale cloud operators (collectively, the "Key Customers"). Based on the financial information provided, the Key Customers collectively accounted for approximately 68% of the Company's FY2022 revenue, representing approximately $212 million of the Company's total revenue of $312 million. This level of customer concentration is a notable risk factor for Halcyon. The loss of any single Key Customer, or a material reduction in orders from any such customer, could have a material adverse effect on Vectris's business, financial condition, and results of operations.
Master Supply Agreements. We have reviewed the master supply agreements (and associated statements of work, purchase order terms, and pricing schedules) with each of the three Key Customers. The key terms of these agreements are summarized as follows:
• Contract terms range from two (2) to five (5) years, with varying renewal provisions (automatic renewal in one case, mutual option to renew in the other two).
• Two of the three agreements contain change-of-control provisions that are triggered upon a change of control of Vectris. In one case, the provision requires written notice to the customer within thirty (30) days following a change of control. In the second case, the provision requires the prior written consent of the customer to any assignment of the agreement in connection with a change of control.
• One Key Customer agreement, representing estimated FY2022 revenue of approximately $85 million, includes a change-of-control clause that grants the customer a right to terminate the agreement within ninety (90) days following a change of control if the acquirer is a "competitor" of the customer as defined in the agreement. This provision presents a potentially significant risk, as the contractual definition of "competitor" may encompass Halcyon or entities within the Halcyon corporate group. A detailed analysis of the "competitor" definition and its applicability to Halcyon is a priority open item.
Risk Assessment and Open Item. The change-of-control termination right in the approximately $85 million customer contract described above is the most significant customer contract risk identified in our review. If Halcyon is deemed a "competitor" under the contractual definition, the customer would have the unilateral right to terminate the agreement within 90 days following the closing of the Merger. The loss of an $85 million annual revenue stream would be highly material to Vectris's post-closing business. We need to assess whether the definition of "competitor" in the agreement would encompass Halcyon and, if so, whether the customer's consent to the Transaction should be obtained prior to closing as a condition to the Merger, or whether this is more appropriately addressed as a post-closing integration matter with appropriate risk allocation in the Merger Agreement.
Recommendation. We recommend that the Merger Agreement include robust representations regarding the Company's material contracts, including representations that no material contract has been breached or terminated, that the Company has provided complete and accurate copies of all material contracts, and that the execution and delivery of the Merger Agreement and the consummation of the transactions contemplated thereby will not result in a breach, default, or right of termination under any material contract except as set forth in the disclosure schedules. Disclosure Schedule 3.14 (Material Contracts) should capture all change-of-control provisions in material contracts. Additionally, the deal team should consider whether obtaining specific customer consents should be made a condition to closing and, if so, under what circumstances the failure to obtain such consents would permit either party to terminate the Merger Agreement.
B. Supplier and Foundry Agreements
As a fabless semiconductor company, Vectris relies on third-party foundries for wafer fabrication and on third-party outsourced semiconductor assembly and test providers ("OSATs") for packaging and testing of its products. The Company's supply chain relationships are therefore critical to its ongoing operations.
We have reviewed the Company's primary foundry agreement and its two principal OSAT agreements. The foundry agreement has a three-year term with options for renewal by mutual agreement. The OSAT agreements have terms of two and three years, respectively. We have not identified any change-of-control provisions in the foundry agreement or either OSAT agreement that would be triggered by the Merger. This is a favorable finding, as it reduces the risk of supply chain disruption in connection with the Transaction.
The foundry agreement contains volume commitment provisions requiring Vectris to purchase minimum quarterly volumes of wafer starts. Based on our review of the Company's production records and financial data, Vectris has historically met or exceeded these minimum volume thresholds, and there is no indication that the Company is at risk of failing to meet its volume commitments in the near term.
We have not identified any sole-source dependencies for critical fabrication processes. In particular, the Company's 800G transceiver modules, which represent its highest-volume product line, are dual-sourced from two independent foundries. This dual-sourcing arrangement mitigates supply chain risk and is a positive factor in our assessment.
C. Joint Development and Collaboration Agreements
We have identified two joint development agreements ("JDAs") with third parties relating to next-generation co-packaged optics technology. These JDAs involve collaborative research and development activities and include provisions governing the allocation of intellectual property rights arising from the joint development work.
One JDA includes IP ownership and licensing provisions that merit further review, including provisions relating to the ownership of jointly developed inventions, the grant of licenses to each party for use of jointly developed IP, and restrictions on sublicensing. These provisions will be analyzed in detail in the forthcoming IP Due Diligence Memorandum to be prepared by Tiffany Rosenthal and dated July 21, 2023.
Both JDAs contain confidentiality provisions that survive the termination or expiration of the agreement, typically for a period of five to seven years. We will review these confidentiality provisions in conjunction with our analysis of the IP ownership provisions to ensure that Halcyon, as the post-closing parent of Vectris, will have adequate access to the technology and information developed under these agreements.
D. Real Property Leases
Vectris does not own any real property. The Company leases its principal offices and facilities in three locations:
1. Headquarters — San Jose, California. Vectris leases approximately 85,000 square feet of office and laboratory space at 4750 Ridgepoint Drive, Suite 300, San Jose, California 95134. The lease term extends through December 31, 2028, with one five-year renewal option exercisable by the tenant. Current annual base rent is approximately $4.8 million. The lease includes a provision requiring the landlord's prior written consent to any assignment of the lease, including an assignment in connection with a change of control of the tenant. This is a standard commercial lease provision and is not expected to be problematic; landlord consent for assignments in connection with mergers and acquisitions is routinely obtained.
2. Austin, Texas. Vectris leases approximately 22,000 square feet of office space for its Austin-based engineering team. The lease term extends through 2026 with no change-of-control consent requirement.
3. Portland, Oregon. Vectris leases approximately 15,000 square feet of office space for its Portland-based engineering team. The lease term extends through 2027 with no change-of-control consent requirement.
We recommend that the Merger Agreement include representations regarding the Company's leased properties and that landlord consent for the San Jose headquarters lease be obtained as a matter of prudent practice, either prior to or promptly following closing.
E. Financing and Debt Instruments
Vectris does not have any outstanding long-term debt. The Company maintains a $50 million revolving credit facility (the "Revolver") with a regional commercial bank. As of the most recent financial statements reviewed, approximately $12 million was drawn on the Revolver. The Revolver includes a standard change-of-control provision requiring repayment of all outstanding amounts upon a change of control of the borrower.
Recommendation. We recommend that the closing mechanics in the Merger Agreement provide for the payoff of all outstanding amounts under the Revolver at or immediately prior to the effective time of the Merger. A payoff letter from the lending bank should be obtained in advance of closing, and the payoff amount should be included in the funds flow memorandum. The payoff of the Revolver should be coordinated with the financing arrangements for the Transaction and factored into the aggregate closing payment calculation.
V. Intellectual Property — Preliminary Findings
This section provides a high-level overview of the preliminary intellectual property findings from our review. A detailed analysis of Vectris's patent portfolio, trade secrets, trademarks, copyrights, and license agreements will be provided in a separate IP Due Diligence Memorandum being prepared by Tiffany Rosenthal, anticipated to be dated July 21, 2023.
Patent Portfolio. Vectris holds 187 issued U.S. patents and has 43 pending U.S. patent applications. The patent portfolio covers a range of technologies central to the Company's business, including silicon photonics transceiver technology, optical coupling methods, waveguide architectures, and co-packaged optics chiplet designs. The patent portfolio is core to Vectris's competitive position in the silicon photonics market and is widely regarded as a key driver of the Company's valuation. Based on our preliminary review, the patent portfolio appears to be strategically assembled and broadly aligned with the Company's current and planned product lines.
Chain-of-Title Issues. Our preliminary review has identified potential chain-of-title issues with respect to a small number of patents — approximately five to seven — that were assigned by early-stage employees of Vectris (including founders and early engineering hires) during the period prior to the Company's Series A financing. In certain cases, the assignment documentation on file with the U.S. Patent and Trademark Office may be incomplete, unrecorded, or ambiguous. These chain-of-title issues, while not uncommon for early-stage technology companies, require further investigation. Corrective assignments should be obtained from the relevant individuals prior to or at closing, if feasible, and the Merger Agreement should include appropriate representations and indemnification provisions to allocate risk with respect to any unresolved title defects.
License-In Agreements. We have identified license agreements under which Vectris holds licenses from two third-party patent holders. These licenses appear to be non-exclusive and perpetual in duration, but the specific terms regarding change-of-control provisions, assignability, and sublicensing require further review. If either license is non-assignable or contains provisions that would be triggered by the Merger, the parties may need to obtain the licensor's consent or negotiate amendments to the license agreements.
Infringement Claims. We have not identified any active patent infringement litigation in which Vectris is a defendant. However, the Data Room materials include a cease-and-desist letter received by Vectris in Q1 2023 from a competitor alleging potential infringement of two of the competitor's patents relating to certain optical coupling techniques. Vectris's outside IP counsel prepared and delivered a written opinion of non-infringement, and the matter is currently dormant — no litigation has been filed, and there has been no further correspondence from the competitor since the delivery of the non-infringement opinion. While this matter does not presently rise to the level of a material risk, it should be monitored for any further developments, and the Merger Agreement's IP representations should address known infringement allegations.
Open Items. The following IP-related items remain open and will be addressed in the forthcoming IP Due Diligence Memorandum and through ongoing workstream activities:
• Full freedom-to-operate analysis with respect to Vectris's current product lines and planned next-generation products;
• Confirmation that all current and former employees who contributed to the development of Company intellectual property have executed valid invention assignment agreements;
• Detailed review of the IP ownership and licensing provisions in the joint development agreements identified in Section IV.C above; and
• Assessment of the assignability and change-of-control provisions in the license-in agreements from third-party patent holders.
VI. Litigation and Proceedings
A. Pending Litigation
Our review of the litigation files in the Data Room, supplemented by public court records searches, has identified two pending litigation matters involving Vectris. Each is described below.
1. Employment Dispute — Wrongful Termination Claim.
A former senior engineer of Vectris filed a complaint in Santa Clara County Superior Court in February 2023, alleging wrongful termination in violation of public policy. The plaintiff contends that his employment was terminated in retaliation for raising safety concerns related to testing protocols in the Company's San Jose laboratory. Vectris denies the allegations in their entirety and has stated, through its outside employment counsel, that the plaintiff's termination was the result of documented performance deficiencies unrelated to any safety complaints.
The matter is in early discovery. No depositions have been taken, and no dispositive motions have been filed. Vectris's outside employment counsel assesses the risk of an adverse outcome as low and estimates the Company's potential exposure, in the event of a settlement or adverse judgment, at less than $500,000, inclusive of potential attorneys' fees.
2. Commercial Dispute — Breach of Contract (Former Distributor).
A former distributor of Vectris products, whose distribution agreement was terminated by the Company in 2022, has filed a breach-of-contract action in the United States District Court for the Northern District of California. The former distributor alleges that Vectris wrongfully terminated the distribution agreement and seeks approximately $2.3 million in alleged lost commissions, together with attorneys' fees and costs.
Vectris has filed a motion to dismiss the complaint, arguing that the termination was expressly permitted under the distribution agreement's termination-for-convenience clause and that the former distributor has failed to state a claim upon which relief can be granted. The motion to dismiss is fully briefed and awaiting ruling. Vectris's outside litigation counsel believes the claim is without merit and expects the motion to dismiss to be granted in whole or in substantial part.
Assessment. Neither of the pending litigation matters described above, individually or in the aggregate, is expected to have a material adverse effect on Vectris's business, financial condition, or results of operations. The aggregate potential exposure for both matters is less than $3 million, which is de minimis relative to the Company's scale and the Transaction value.
Recommendation. Both matters should be disclosed in Disclosure Schedule 3.8 (Litigation) to the Merger Agreement. We recommend obtaining detailed litigation summaries from Vectris's outside counsel for each matter, including an assessment of the probable range of outcomes, the current procedural status, anticipated near-term developments, and the estimated costs to resolve each matter. These summaries should be reviewed and, if appropriate, shared with Halcyon's deal team to inform the risk allocation provisions of the Merger Agreement.
B. Threatened Litigation
The Q1 2023 cease-and-desist letter regarding alleged patent infringement, described in Section V above, represents a potential source of future litigation. As noted, the matter is currently dormant, and Vectris's outside IP counsel has provided an opinion of non-infringement. We are not aware of any indication that the competitor intends to pursue litigation at this time, but the matter should continue to be monitored.
No other threatened litigation has been identified in the Data Room materials or through management interviews conducted to date. We recommend that the Merger Agreement include a representation by Vectris that, to the knowledge of the Company, there are no additional threatened claims, demands, or proceedings that have not been disclosed.
C. Government Investigations
No pending or threatened government investigations have been disclosed by Vectris in the Data Room or through management representations to date. This includes investigations by federal and state regulatory agencies, enforcement actions, and inquiries from any governmental authority, including, without limitation, the Securities and Exchange Commission, the Department of Justice, the Federal Trade Commission, the Bureau of Industry and Security, and applicable state attorneys general.
Open Item. We recommend confirming through a formal management representation letter, signed by Dr. Raghavan and Ms. Lau, that no inquiries from any governmental authority (including export control authorities such as the Bureau of Industry and Security) are pending, threatened, or, to the knowledge of the Company, contemplated. This representation should cover the period from January 1, 2020 through the date of the representation.
VII. Employee and Labor Matters
A. Workforce Overview
As of the most recent headcount data provided, Vectris employs approximately 1,450 individuals. The Company's workforce is primarily concentrated at its headquarters in San Jose, California, with additional engineering staff located at its offices in Austin, Texas and Portland, Oregon. The workforce is composed primarily of engineers (approximately 65%), with the remainder distributed among sales, marketing, operations, and general and administrative functions.
Vectris has no collective bargaining agreements and its workforce is not represented by any labor union. The Company has not experienced any work stoppages, strikes, or other labor disturbances. We have not identified any pending or threatened union organizing activity.
The Company reports a voluntary attrition rate of approximately 8% for FY2022, which is consistent with, and at the lower end of, industry norms for the semiconductor sector. This relatively low attrition rate suggests a stable and engaged workforce, which is a positive indicator for post-closing integration.
B. Key Executives and Employment Agreements
We have reviewed the employment agreements for the Company's four named executive officers: Dr. Anand Raghavan (CEO), Margaret Sørensen (President & COO), Julian Tate (CFO), and Rebecca Lau (General Counsel & Corporate Secretary). Each agreement has been reviewed for provisions relating to compensation, severance, change-of-control payments, non-competition and non-solicitation restrictions, and intellectual property assignment obligations.
Change-of-Control Provisions. All four executive employment agreements contain change-of-control provisions that will be triggered by the consummation of the Merger. The key terms are as follows:
• Dr. Anand Raghavan (CEO): Double-trigger severance arrangement — severance benefits are payable only if (i) a change of control occurs and (ii) Dr. Raghavan's employment is terminated by the Company without cause, or Dr. Raghavan resigns for good reason, in each case within twelve (12) months following the change of control. Severance amount: twenty-four (24) months of base salary plus target annual bonus. In addition, all outstanding equity awards accelerate in full upon a qualifying termination.
• Margaret Sørensen (President & COO): Double-trigger severance arrangement on the same terms as Dr. Raghavan. Severance amount: eighteen (18) months of base salary plus target annual bonus. Full acceleration of outstanding equity awards upon qualifying termination.
• Julian Tate (CFO): Single-trigger equity acceleration upon change of control; severance of twelve (12) months of base salary payable upon termination without cause or resignation for good reason within twelve (12) months following the change of control.
• Rebecca Lau (General Counsel): Single-trigger equity acceleration upon change of control; severance of twelve (12) months of base salary payable upon termination without cause or resignation for good reason within twelve (12) months following the change of control.
Estimated Aggregate Change-of-Control Payments. Based on current base salaries and target bonus amounts, the estimated aggregate cash severance obligations for the four named executive officers, assuming all qualifying terminations occur, is approximately $8.5 million. This figure excludes the value of accelerated equity awards, which will be separately quantified based on the final per-share merger consideration and the exercise prices and vesting schedules of each executive's outstanding options and RSUs. The aggregate change-of-control payment obligations should be factored into the deal economics and reflected in the closing payment calculations or disclosed in the SEC proxy statement.
Restrictive Covenants. Dr. Raghavan's employment agreement includes a three-year post-termination non-competition and non-solicitation covenant, and Ms. Sørensen's agreement includes a two-year non-competition covenant. These existing restrictive covenants will provide Halcyon with meaningful protection against competitive activity by the two most senior executives of Vectris following the closing. We note that the Merger Agreement is expected to include a separate three-year post-closing non-competition and non-solicitation covenant applicable to Vectris founders, which would overlap with and reinforce the existing contractual restrictions.
Recommendation. The aggregate change-of-control severance obligations should be factored into the transaction economics. In addition, the deal team should consider whether retention arrangements (such as new employment agreements, retention bonuses, or equity grants in Halcyon) should be negotiated with key executives to incentivize their continued service during the post-closing integration period. The terms of any such retention arrangements should be coordinated with the provisions of the Merger Agreement and the SEC proxy statement disclosures.
C. Employee Benefit Plans
We have reviewed the Company's principal employee benefit plans, including the following:
• 401(k) Plan. The Company maintains a standard safe-harbor 401(k) plan. The plan document has been reviewed and appears to comply with applicable ERISA and Internal Revenue Code requirements. No issues have been identified with respect to the plan's design, administration, or funding. The Company makes safe-harbor matching contributions, which eliminates the need for annual nondiscrimination testing.
• Health and Welfare Plans. The Company provides standard health and welfare benefits to its employees, including medical, dental, vision, life insurance, and short- and long-term disability coverage. These plans appear to be fully insured and are administered by reputable third-party administrators. No unusual features or compliance issues have been identified.
• 2019 Equity Incentive Plan. As described in Section III.D above, all outstanding options and RSUs have been granted under the Plan. The Plan provides that, upon a change of control of the Company, outstanding awards may be assumed, substituted, or cashed out at the discretion of the board or the acquiring company. In the Transaction, it is anticipated that all outstanding options and RSUs will be cashed out for a per-share amount equal to the merger consideration of $13.70 less, in the case of options, the applicable exercise price.
The Company does not maintain any defined benefit pension plans, and there are no post-retirement health or welfare benefit obligations. This is a favorable finding, as it eliminates a potentially significant category of unfunded liabilities.
WARN Act Analysis. We have conducted a preliminary analysis of the Company's obligations under the federal Worker Adjustment and Retraining Notification Act ("WARN Act") and the California WARN Act. Based on information received to date, there are no planned layoffs or plant closings that would trigger federal or California WARN Act notification obligations prior to or in connection with the closing of the Merger. Any post-closing workforce restructuring or reductions-in-force undertaken by Halcyon during the integration period will need to be separately assessed for WARN Act compliance.
D. ERISA and Tax-Qualified Plan Compliance
Our preliminary review indicates that Vectris's employee benefit plans are in compliance with applicable requirements under the Employee Retirement Income Security Act of 1974, as amended ("ERISA"), the Internal Revenue Code, and applicable state laws. The Company has obtained a favorable IRS determination letter for its 401(k) plan, confirming the plan's tax-qualified status. No amendments have been made to the plan since the date of the determination letter that would be expected to adversely affect the plan's qualified status.
We are not aware of any pending or threatened audits, investigations, or enforcement actions by the Department of Labor, the IRS, or any other governmental authority relating to the Company's employee benefit plans.
Open Item. We recommend obtaining representations from Vectris regarding compliance with all applicable employment laws and regulations, including California-specific requirements such as meal and rest break requirements, employee classification (exempt vs. non-exempt), pay equity, and expense reimbursement. California has some of the most employee-protective labor and employment laws in the United States, and compliance deficiencies in these areas can result in significant class action exposure. Given the concentration of the Company's workforce in California, this is an area that warrants careful attention.
VIII. Regulatory and Compliance Matters
A. Antitrust / Competition
A detailed antitrust risk assessment has been prepared separately by Howard Bellamy of C&H in a memorandum dated July 10, 2023 (the "Antitrust Memo"). The findings summarized below are drawn from the Antitrust Memo and from our review of the competitive landscape as it relates to the Transaction.
Market Share Overlap. The Transaction presents significant antitrust risk due to the substantial competitive overlap between Halcyon and Vectris in the market for silicon photonics transceiver modules for hyperscale data center interconnects. Based on publicly available market data and internal estimates provided by both companies, the combined U.S. market share of Halcyon and Vectris in this product category is approximately 47% (Halcyon approximately 19%, Vectris approximately 28%). In the European Economic Area, the combined market share in the more narrowly defined co-packaged optics chiplet segment is estimated at approximately 38%.
Market shares of this magnitude are likely to attract enhanced scrutiny from the U.S. Department of Justice Antitrust Division ("DOJ") and the European Commission's Directorate-General for Competition ("DG COMP"). Under current DOJ enforcement guidelines, market shares exceeding 30% in a relevant market are presumed to create or enhance market power, and the combined 47% share significantly exceeds this threshold.
Filing Requirements. The Transaction will require the filing of a pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act"), as the size-of-transaction and size-of-person thresholds are clearly met. The Transaction will also require notification under the European Union Merger Regulation ("EUMR"), as the applicable Community-dimension turnover thresholds are exceeded based on the worldwide and EU-specific revenues of the parties.
Risk Assessment. A Second Request from the DOJ is a material risk. Based on our analysis, we believe it is more likely than not that the DOJ will issue a Second Request, which would significantly extend the regulatory review timeline and impose substantial document production and compliance costs. In the European Union, a Phase II investigation by the European Commission is possible, although we currently assess this risk as somewhat lower than the Second Request risk in the U.S.
Antitrust approval is expected to be the most significant regulatory condition to the closing of the Merger. The timeline for obtaining clearance could extend to nine to twelve months or longer in the event of a Second Request, and there is a risk — which we assess as non-trivial but not probable — that the DOJ could seek to block the Transaction or require significant divestitures as a condition to clearance.
Recommendation. The Merger Agreement should include the following provisions to address antitrust risk:
• Regulatory Efforts Covenants. Robust covenants requiring both parties to use their best efforts (or a negotiated standard such as "commercially reasonable efforts" or a defined "hell or high water" commitment) to obtain all necessary regulatory approvals. Target counsel at WPL will likely insist on a strong efforts standard, potentially including a "hell or high water" clause requiring Halcyon to agree to divestitures, hold-separate arrangements, or other remedies necessary to obtain antitrust clearance, up to a specified materiality threshold.
• Outside Date. An Outside Date (also referred to as a "drop-dead date" or "long-stop date") with sufficient runway to accommodate extended regulatory review processes. We recommend an initial Outside Date of 180 days from signing, with an automatic 90-day extension if the sole unsatisfied closing condition at the initial Outside Date is the receipt of antitrust approvals.
• Reverse Break-Up Fee. A reverse break-up fee payable by Halcyon to Vectris in the event the Merger Agreement is terminated due to the failure to obtain antitrust approvals. Target counsel will likely seek a reverse break-up fee in the range of 3% to 4% of the aggregate deal value ($24 million to $32 million). The appropriate level of the reverse break-up fee should be negotiated taking into account the degree of antitrust risk, market precedent for comparable semiconductor transactions, and Halcyon's willingness to accept remedies.
B. Export Controls and CFIUS
Export Controls. Vectris's products include advanced photonics components that may be subject to the Export Administration Regulations ("EAR") administered by the U.S. Department of Commerce, Bureau of Industry and Security ("BIS"). We have reviewed the Company's export compliance program and have found it to be well-established, with a dedicated export compliance officer, written compliance procedures, and a training program for employees engaged in international sales and technology transfer activities. Based on our preliminary review, the Company appears to have a strong compliance culture with respect to export controls, and we have not identified any material violations or pending enforcement actions.
CFIUS. Because Halcyon is a German company (and thus a foreign person for purposes of the Committee on Foreign Investment in the United States ("CFIUS")), and because the Transaction involves the acquisition of a U.S. business engaged in the development and production of semiconductor technology, a CFIUS filing may be warranted or advisable, even if not mandatory under the applicable regulations.
Our preliminary assessment is that the CFIUS risk is moderate. Vectris's products are commercial data center components designed for civilian hyperscale cloud computing applications and are not primarily used in military, intelligence, or national security applications. Germany is a close ally of the United States and a member of NATO, which reduces (but does not eliminate) the risk of a CFIUS challenge. However, the semiconductor industry has been the subject of heightened CFIUS scrutiny in recent years, and the U.S. government has demonstrated a willingness to review transactions involving advanced semiconductor and photonics technologies.
Open Item. We recommend conducting a detailed CFIUS analysis to determine whether a voluntary CFIUS filing should be made. If a filing is advisable, the timing of the CFIUS process should be coordinated with the HSR/EUMR filing timeline to avoid unnecessary delays. Howard Bellamy will be leading this analysis, with a target completion date of July 28, 2023.
C. Environmental
Vectris is a fabless semiconductor company and does not operate any manufacturing facilities, wafer fabrication plants, or other industrial operations. The Company's business is limited to the design, development, and sale of semiconductor products, with all manufacturing outsourced to third-party foundries and OSATs.
As a result, Vectris does not hold any environmental permits, does not generate hazardous waste, and has no exposure to Superfund liability or other environmental cleanup obligations. The leased premises occupied by the Company have been subject to standard Phase I environmental site assessments conducted by the landlords, and no environmental issues have been flagged in any such assessments.
Environmental risk is assessed as low. We do not anticipate that environmental matters will present any material risk or impediment to the Transaction.
D. Data Privacy and Cybersecurity
Vectris collects and processes a relatively limited volume of personal data in the course of its business operations. The personal data collected by the Company primarily consists of (i) employee personal data, including names, contact information, Social Security numbers, compensation data, and benefits information, and (ii) customer and business partner technical contact information, such as names, email addresses, and phone numbers of engineering and procurement personnel at customer organizations.
We have reviewed the Company's privacy policy as published on its website and find it to be generally consistent with the requirements of the California Consumer Privacy Act ("CCPA") and other applicable state privacy laws. The Company does not appear to be subject to the European Union General Data Protection Regulation ("GDPR") based on its current operations, although this assessment should be revisited if the Company has or obtains European customers or employees.
Vectris has not disclosed any material data breaches or cybersecurity incidents during the past three years. The Company maintains a cybersecurity program that includes industry-standard safeguards, and the Company has obtained a SOC 2 Type II certification, which provides third-party assurance regarding the effectiveness of its security controls.
Open Item. We recommend verifying compliance with any customer-specific data-handling requirements set forth in the major supply agreements, particularly with respect to the Key Customers, which may impose heightened data protection and information security standards on their suppliers.
IX. Tax Matters — Preliminary
As noted above, detailed tax due diligence is being conducted by Thornbury Wight LLP under the direction of engagement partner Gavin Ashmore. The findings set forth in this section are preliminary and are subject to the more comprehensive analysis to be provided by Thornbury Wight.
Tax Filings. Vectris files U.S. federal income tax returns and state income tax returns in California, Texas, Oregon, and New York. Based on our preliminary review, the Company's tax filing obligations appear to be current, and no tax audits are currently pending with the IRS or any state taxing authority.
R&D Tax Credits. Vectris has claimed research and development tax credits under Section 41 of the Internal Revenue Code in connection with its silicon photonics research and development activities. The documentation supporting these credit claims appears to be organized and substantive, but the credits will require verification and validation by Thornbury Wight as part of the detailed tax due diligence process. R&D tax credits are a common area of IRS scrutiny, and any material disallowance of previously claimed credits could give rise to additional tax liability.
Profitability and NOLs. Vectris has been consistently profitable since FY2020 and does not have significant net operating loss carryforwards. This is a favorable finding, as it reduces the complexity of the tax analysis and eliminates concerns about the usability or impairment of NOL assets in connection with the Transaction.
Transaction Structure. The proposed reverse triangular merger structure contemplates that Vectris stockholders will receive cash consideration in exchange for their shares of Vectris common stock. The Transaction is intended to be taxable to Vectris stockholders and is not intended to qualify as a tax-free reorganization under Section 368 of the Internal Revenue Code. The tax consequences to Vectris stockholders will be disclosed in the SEC proxy statement.
Open Items. The following tax-related items remain open:
• Confirm that there are no tax indemnification agreements or tax-sharing arrangements between Vectris and any former affiliates, partners, or related parties;
• Verify the Company's state income tax nexus positions, particularly with respect to states in which the Company has customers or employees but may not be filing returns; and
• Complete the detailed tax due diligence review being conducted by Thornbury Wight LLP.
X. Insurance Coverage
We have reviewed Vectris's insurance program, which includes the following principal policies:
• General Liability Insurance. Standard commercial general liability policy with coverage limits consistent with industry norms.
• Directors' and Officers' (D&O) Insurance. Current D&O policy with an aggregate coverage limit of $25 million. The policy is in force and provides coverage for claims arising from acts or omissions of the Company's directors and officers in their capacities as such. In connection with the Merger, a "tail" policy (also known as a "run-off" policy) will need to be obtained to provide continued D&O coverage for a period of six (6) years following the closing, which is the standard run-off period for D&O tail policies in change-of-control transactions.
• Errors and Omissions / Professional Liability Insurance. E&O policy providing coverage for claims arising from the Company's professional services and product design activities.
• Cyber Liability Insurance. Cyber liability policy providing coverage for data breach response costs, business interruption losses, and third-party claims arising from cybersecurity incidents.
• Property and Casualty Insurance. Standard property and casualty policy covering the Company's leased premises, equipment, and business personal property.
We have not identified any material claims history under any of the Company's insurance policies.
Representation and Warranty (R&W) Insurance. In connection with the Transaction, representation and warranty insurance is being arranged to provide Halcyon with coverage for losses arising from breaches of the representations and warranties made by Vectris in the Merger Agreement. The R&W insurance is being brokered by Atlas Transactional Insurance Group, Inc. (broker contact: Martin Cavallo) and is expected to be underwritten by Pinnacle Specialty Underwriters, Ltd. (underwriter contact: Fiona Brennan).
The key terms of the proposed R&W insurance policy are as follows:
Recommendation. The R&W insurance underwriting process should be finalized promptly to ensure that the policy scope and terms are aligned with the representations and warranties in the Merger Agreement. The underwriter will conduct its own due diligence review, and the findings from this and subsequent due diligence memoranda will be shared with the underwriter (subject to applicable confidentiality and privilege considerations). Any exclusions or limitations in the R&W policy should be carefully reviewed and negotiated to minimize gaps in coverage. Oliver Mackenzie is coordinating with Martin Cavallo at Atlas Transactional Insurance Group on an ongoing basis.
XI. Summary of Key Risk Areas and Recommendations
Based on our preliminary due diligence review, we have identified the following key risk areas, presented in descending order of assessed significance, together with our recommendations for each:
A. Antitrust Approval Risk — HIGH
The combined U.S. market share of Halcyon and Vectris in the silicon photonics transceiver module market is approximately 47%, and the combined EEA market share in the co-packaged optics chiplet segment is approximately 38%. These market shares significantly exceed the thresholds that typically trigger enhanced regulatory scrutiny and present a material risk of a Second Request from the DOJ and a possible Phase II investigation by the European Commission. Antitrust approval is expected to be the most significant regulatory condition to closing.
Recommendations:
• Negotiate an appropriate reverse break-up fee. Target counsel at WPL will likely push for a fee in the range of 3% to 4% of aggregate deal value ($24 million to $32 million). The fee should be payable by Halcyon in the event the Merger Agreement is terminated due to the failure to obtain required antitrust approvals.
• Include robust regulatory efforts covenants in the Merger Agreement, with careful negotiation of the standard of efforts and the scope of any remedies that Halcyon may be required to accept (including potential divestitures or behavioral commitments).